CureMatch
Match the known biology of your unique tumor to all possible treatment options. Get biomarker testing and get “CureMatched.”
The Biomarker Academy™
Free to the “cancer-concerned” public of patients, loved ones/friends, and patient advocates who want to learn “cancer biomarkers as a second language.” This unique, live and interactive course teaches basic vocabulary necessary to advocate for biomarker testing, to better understand test results, and to have more educated conversations with the oncologist. Contact My Biomarker Navigator™to register for the next course offering.
Articles & Posts
The 10 Tissue Tenets™
What you need to know before surgery or biopsy about use of your tissue. Make sure there is enough for biomarker testing – now and later!
Keeping Up with The Biomarkers
We can’t expect oncologists to know everything there is to know about biomarkers. Everybody needs help!
The BOM (Biomarker of the Month) Archive
HER2 Low in Breast Cancer
There’s a new HER2 category in town called “HER2 Low.” In breast cancer, HER2 protein on tumor cells was traditionally measured as positive or negative, but now there’s a third important category of “low.” If you ever had HER2 testing and were told the result was “negative,” “equivocal,” “absent,” or “low,” please revisit these test results, because you may benefit from a new drug approved for HER2 low breast cancer!
ALK Translocation in NSCLC
November is lung cancer awareness month, so the Biomarker of the Month (BOM) is ALK translocation (“ALK”). This biomarker is rare in lung cancer, found in 3-5% of non-small cell lung adenocarcinomas, and even more rare in squamous cell lung cancer. However, there are very effective treatments that target ALK, so make sure your tissue or blood sample has been tested for ALK! Visit the excellent patient-led ALK Positive organization to learn more.
KRAS Mutation in Colon Cancer
March is National Colon Cancer Awareness month. Make sure you get appropriate testing for ALL relevant biomarkers! These include KRAS, NRAS, BRAF, HER2, MMR, MSI, and in some cases NTRK. Our March Biomarker of the Month (BOM) is KRAS. About 40% of colon cancers have a KRAS mutation, most commonly the KRAS G12D and G12V mutations. Look for new clinical trials for drugs targeting KRAS mutations like G12D! Reach out to My Biomarker Navigator™ for help.